Age-related Macular Degeneration (AMD) Market Share, Size, Trends, Industry Analysis Report
By Drugs (Lucentis, Eylea, Avastin, Others); By Product; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2025 - 2034
- Published Date:Sep-2025
- Pages: 114
- Format: PDF
- Report ID: PM1128
- Base Year: 2024
- Historical Data: 2020 - 2023
The global Age-related Macular Degeneration (AMD) Market was valued at USD 11.79 billion in 2024 and is expected to grow at a CAGR of 8.0% during the forecast period. Rising Research and Development (R&D) investments, as well as increased approvals for new medications, are important drivers of Age-related Macular Degeneration (AMD) market expansion.
Key Insights
- By product, the wet AMD subsegment held the largest share in 2024, primarily due to the availability of approved and highly effective anti-vascular endothelial growth factor (Anti-VEGF) drug treatments.
- By drugs, the Eylea drug subsegment held the largest share in 2024, contributing the largest revenue share to the overall market for AMD drugs.
- By route of administration, the intravenous route of administration held the largest share in 2024, as the most effective treatments for wet AMD are anti-VEGF agents that must be directly injected into the eye.
- By distribution channel, the Hospital pharmacies subsegment held the largest share in 2024 because AMD treatment, especially the frequent intravitreal injections.
- By region, North America held the largest share in 2024, accounting for the largest revenue share, mostly driven by the United States. This dominance is due to a high prevalence of AMD in the aging population, sophisticated healthcare infrastructure, and high patient awareness.
Industry Dynamics
- The rapidly expanding global geriatric population is a primary growth factor, significantly increasing the patient pool susceptible to vision loss.
- Technological advancements, especially in anti-VEGF therapies, are major drivers, offering more durable treatment options and easing the patient burden.
- A growing focus on research and development (R&D) for dry-form treatments is also shaping the industry outlook.
Market Statistics
- 2024 Market Size: USD 11.79 billion
- 2034 Projected Market Size: USD 25.40 billion
- CAGR (2025-2034): 8.0%
- North America: Largest market in 2024
-market-size-by-region-2020-2034.png)
To Understand More About this Research: Request a Free Sample Report
AI Impact on the Market
- AI algorithms, particularly those using deep learning, can analyze retinal images from fundus photography or optical coherence tomography (OCT) scans with high speed and precision.
- AI models can analyze complex imaging data to predict how a patient's AMD will progress and how they might respond to treatments, such as anti-vascular endothelial growth factor (anti-VEGF) injections.
- By automating the analysis of retinal images, AI quickly flag images that show signs of AMD.
For instance, in October 2021, Roche has announced the approval of Susvimo (ranibizumab injection) 100 mg/mL by the US Food and Drug Administration (FDA) of intravenous injection use through an ocular augmentation in people with age-related macular degeneration (AMD) who have earlier received two of the anti-vascular endothelial growth factor (VEGF) infusions.
Also, the United States Food and Drug Administration (FDA) granted GT005; an experimental, one-time AAV gene therapy received fast-track designation in September 2020. Gyroscope Therapeutics Limited has developed GT005, which is a one-time experimental gene treatment for GA owing to AMD that is given under the retina and is based on AAV2.
Industry Dynamics
Growth Drivers
The global burden of AMD continues to rise at an unprecedented speed as the global population grows and the demographics reflect a majority of older people. AMD is a primary cause of visual loss in the elderly, according to the National Eye Institute. Furthermore, those over the age of 60 are at a higher risk of having the condition.
AMD is predicted to become more common as the world's population ages, with a higher frequency in Western countries. According to the Globe Health Organization, there are currently around 1.1 billion tobacco users in the world, with that figure likely to double by 2050 if current trends continue. As a result, cigarette use is thought to be a major contributor to the global increase in AMD prevalence.
Furthermore, as the global population of people aged 60 and up grows, so does the prevalence of AMD. According to the United Nations' Globe Population Prospects report, there were around 962 million individuals aged 60 and more in the world in 2017, with the number predicted to more than double by 2050.
According to WHO, myopia and high myopia were expected to affect around 52.0% and 10.0% of the global population, respectively, by 2050. The prevalence of myopia is high in East Asia, where China, Japan, the Republic of Korea, and Singapore.
-market-size-worth-$25.40-billion-by-2034.png)
Report Segmentation
The market is primarily segmented based on product, drugs, route of administration, distribution channel, and region.
|
By Product |
By Drugs |
By Route of Administration |
By Distribution Channel |
By Region |
|
|
|
|
|
-market-by-product-analysis-2020-2034.png)
Insight by Product
Based on the product segment, the wet AMD segment is expected to be the most significant revenue contributor in the global Age-related Macular Degeneration (AMD) market. Wet age-related macular degeneration is the start of normal blood vessel growth beneath the retina. The expanding geriatric population around the world is producing a high-level demand in the wet age-related macular degeneration market since AMD is the most prevalent cause of significant loss of vision in those over 50 years of age.
The growth is further driven by the higher prevalence of wet AMD in aging populations, the rapid progression of the disease requiring immediate treatment, and increasing awareness about early diagnosis. Additionally, advancements in biologics and anti-VEGF therapies, rising healthcare expenditure, and ongoing clinical trials for novel treatments are further propelling demand in this segment, solidifying its dominant market position.
Geographic Overview
North America had the largest revenue share in the global market in 2024. The rising incidence of the geriatric population and age-related macular degeneration, the participation of important market players, and increased research and development activities are some of the forces influencing Age-related Macular Degeneration (AMD) market expansion in the North American area. Furthermore, the American Macular Degeneration Foundation (AMDF) in the United States disseminated this information to warn AMD patients and eye care professionals about the potential danger.
Around the world, advanced AMD is a primary cause of permanent blindness and visual impairment. As a result, the market is growing as AMD's load grows. Further, Wet age-related macular degeneration is one of the leading causes of visual loss in adults over 65, according to the Canadian Ophthalmological Society.
One of its studies, released in 2019, predicted that by 2032, at least one out of every four Canadians would have age-related macular degeneration. As a result of the aforementioned factors, the market in the region is predicted to develop significantly over the forecast period.
Moreover, Asia Pacific is expected to witness a high CAGR in the global Age-related Macular Degeneration (AMD) market. The sale of medications for exudative AMD in APAC is currently insignificant due to a lack of accessibility and expensive drug costs. The region, however, has a high prevalence of AMD, making it a potentially growing market.
Furthermore, in APAC, the presence of companies involved in the marketing and research of exudative AMD medicines is fairly low. In addition, the region accounts for more than a third of all age-related macular degeneration cases recorded globally therefore demand for wet age-related macular degeneration medications is projected to increase dramatically in the future years.
-market-trends-by-region-2020-2034.png)
Competitive Insight
Some of the major players operating in the global market include Acucela Inc., Alimera Sciences Inc., ALLERGAN, Bausch & Lomb Incorporated, Bayer AG, F. Hoffmann La Roche, GlaxoSmithKline PLC, Novartis AG, Ophthotech Corporation, Pfizer Inc, Regeneron Pharmaceuticals, Rxi Pharmaceuticals Inc., Santen Pharmaceuticals Co., and Valeant Pharmaceuticals International, Inc. among others.
Industry Dynamics
In July 2024, Genentech (Roche) reintroduced Susvimo (100 mg/mL ranibizumab injection) in the U.S. for intravitreal use via ocular implant, indicated for the treatment of neovascular or “wet” age-related macular degeneration (nAMD).
Age-related Macular Degeneration (AMD) Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 11.79 billion |
| Market size value in 2025 | USD 12.71 billion |
|
Revenue forecast in 2034 |
USD 25.40 billion |
|
CAGR |
8.0% from 2025 - 2034 |
|
Base year |
2024 |
|
Historical data |
2020 - 2023 |
|
Forecast period |
2025 - 2034 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2025 to 2034 |
|
Segments covered |
By Product, By Drugs, By Route Of Administration, By Distribution Channel, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Key companies |
Acucela Inc., Alimera Sciences Inc., ALLERGAN, Bausch & Lomb Incorporated, Bayer AG, F. Hoffmann La Roche, GlaxoSmithKline PLC, Novartis AG, Ophthotech Corporation, Pfizer Inc, Regeneron Pharmaceuticals, Rxi Pharmaceuticals Inc., Santen Pharmaceuticals Co., and Valeant Pharmaceuticals International, Inc. |
FAQ's
? The global market size was valued at USD 11.34 billion in 2024 and is projected to grow to USD 25.40 billion by 2034.
? The global market is projected to register a CAGR of 8.0% during the forecast period.
? North America dominated the market share in 2024.
? The Wet AMD segment accounted for the largest share of the market in 2024.
© 2025 Polaris Market Research and Consulting. All rights reserved
